Cognition Therapeutics Inc. (CGTX)
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (90%) **Content type:** Clinical